View source for ICE-R regimen

__NOTOC__
{{SI}}
{{CMG}}; {{AE}} {{AV}}

{{SK}}R-ICE Regimen; RICE Regimen; Rituximab-Ifosfamide-Carboplatin-Etoposide Regimen

==Overview==
{{PAGENAME}} refers to a chemoimmunotherapy regimen consisting of [[rituximab]], [[ifosfamide]], [[carboplatin]] and [[etoposide]] used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63465&ns=NCI_Thesaurus }}</ref>

==Regimen==
{{chemo|R|Rituximab}}

{{chemo|I|Ifosfamide}}

{{chemo|C|Carboplatin}}

{{chemo|E|Etoposide}}

==Indications==
*Relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref>

==References==
{{Reflist|2}}

[[Category:Chemotherapy regimens]]